ImmuPharma (LON:IMM) Trading 28.8% Higher - Here's What Happened

Key Points

• ImmuPharma's stock price surged by 28.8% after trading at a high of GBX 15.23 ($0.21), significantly increasing its trading volume by 451% compared to the average.
• The company reported a net margin of 3,519.56% and a negative return on equity of 131.41%, with analysts forecasting an EPS of -339.0000022 for the current year.
• ImmuPharma is a biopharmaceutical company focusing on peptide-based therapeutics for autoimmune diseases, with its lead program being P140 (Lupuzor™) for Lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report) rose 28.8% during mid-day trading on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares traded hands during mid-day trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The stock's 50 day simple moving average is GBX 3.12 and its 200-day simple moving average is GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.